Viriom

25 articles about Viriom

• Viriom's Single Pill Influenza Treatment Completes Critical Phase I Clinical Trials

  11/20/2023

  Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication.

• Viriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected Patients

  5/4/2020

  Viriom Inc announced the initiation of a Phase 2a study investigating the efficacy of an intramuscular long-acting injectable nanoformulation of VM1500A in HIV-infected patients.

• 

  Insight Report: HIV and AIDS Research and Treatments

  4/21/2020

  BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.

• Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19

  4/8/2020

  Viriom, Inc. announced the initiation of a Phase 2 clinical study to evaluate the efficacy of elsulfavirine in adults with moderate manifestations of COVID-19.

• Viriom donates Elpida to Chinese and Russian governments for experimental use against COVID-19;

  3/24/2020

  Viriom Inc announces the company's activities to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Elpida (elsulfavirine) and Viriom's experimental flu medicines AV5080, AV5124 and AV5126 to determine their efficacy in the treatment of COVID-19.

• Viriom to present results of Phase I study of the long acting injectable formulation of novel NNRTi for treatment of HIV-1 infection at CROI 2020

  2/17/2020

  SAN DIEGO , Feb. 17, 2020 /PRNewswire/ -- Viriom, Inc. will be presenting the results of Phase I study on safety and pharmacology of VM1500-LAI long acting injectable nanoformulation at the Conference on Retroviruses and Opportunistic Infections (CROI 2020). The study will be presented by Professor Robert Murphy, Northwestern University, Chicago, as a late-breaker poster.

• Viriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral Formulation

  12/3/2019

  Viriom Inc (Viriom) announces launching Segment I and Segment II reproductive toxicity studies of Elpida® (elsulfavirine) HIV-1 therapy, supported by preclinical services of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

• Viriom Wins Grant Award to Establish Affiliate in Mainland China

  9/4/2019

  Viriom Inc., has won a grant award in the city of Shaoxing, Zhejiang province, to establish its affiliate in Mainland China.

• Viriom announces NIH/NIAID and Division of AIDS Collaboration with the Long-Acting/Extended Release Antiviral Resource Program

  9/3/2019

  Viriom Inc., a clinical stage antiviral company focused on HIV and viral hepatitis, is developing long-acting versions of its once daily NNRTI inhibitor, elsulfavirine.

• Viriom Signed Licensing Agreement for Indonesia with P.T. Lloyd Pharma

  7/2/2019

   Viriom Inc (San Diego, CA) signed a licensing agreement with P.T. Lloyd Pharma Indonesia as a part of its global strategy to help combat HIV drug resistance problem in developing markets by using innovative, safe and efficacious treatment and prevention options with Elpida® as well as other drugs from Viriom HIV and HBV portfolio.

• Viriom Files for Market Authorization in China

  6/3/2019

  Iain Dukes, CEO of Viriom Inc, presented Viriom's strategy on high growth developing markets, which includes obtaining a market authorization in China, at the 11th ChinaBio Annual International Partnering Conference in Shanghai.

• 

  BioSpace Movers and Shakers: March 1

  3/1/2019

  Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more.

• Viriom Announces New CEO Appointment

  2/25/2019

  Viriom Inc. is pleased to announce the appointment of Iain Dukes, M.A., D.Phil., as its new CEO. Dr. Dukes brings to Viriom over 20 years of extensive experience in drug discovery, pharmaceutical research and business development, as well as in leadership and consulting for numerous biotech and venture capital organizations.

• Viriom China Wins Award at 2018 Zhongguancun International Frontier Science and Technology Innovation Competition

  1/17/2019

  Viriom China has been named the only foreign finalist of the 2018 Zhongguancun International Frontier Science and Technology Innovation Competition.

• Viriom to Report Results from Phase 1b Clinical Trial of Once Weekly Oral HIV Treatment

  12/21/2018

  Viriom, Inc. announced today that it plans to report results from its Phase 1b clinical trial of once weekly dosing of oral elsulfavirine (Elida®, VM1500), a potent long acting nonnucleoside reverse transcriptase inhibitor (NNRTI) in HIV-uninfected volunteers in March 2019.

• Viriom Initiates Phase 1 Clinical Trial of Once Monthly Injectable HIV Treatment

  12/20/2018

  Viriom, Inc. announced that it has initiated the first Phase 1 clinical trial of the long acting nanoformulation of VM1500A in HIV-uninfected volunteers

• Elpida™ Included in Essential Drugs List for HIV-1 in Russia

  9/5/2018

  Viriom's Elsulfavirine (Elpida™)-based regimens for treatment of HIV-1 infection will be available to all patients and physicians in both regionally and federally funded programs in Russia

• Viriom Announces New Director Appointment

  12/6/2017

  Viriom is pleased to announce the appointment of Augustine Lawlor as Director of Viriom.

• Viriom Obtains First Market Approval Of Elsulfavirine (Elpida) For Treatment Of HIV-1 Infection In Russia

  7/25/2017

• Viriom Reports Positive Findings In Phase IIb Study Of Elpida As Compared To Efavirenz In Combination With TDF/FTC At CROI 2017

  2/17/2017